Papillary thyroid cancer (PTC) is the most common pathological subtype of thyroid cancer (TC), and its BRAF mutation rate, especially the point mutation of valine at the 600 positions to glutamate, i.e., BRAFV600E, can reach >80% in Asian populations, which creates a very favorable condition for targeted therapy in this population. Here, BRAF is linked to thyroid cancer.